| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPP2 |
| Uniprot No | Q13103 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-211aa |
| 氨基酸序列 | F PVYDYDPSSL RDALSASVVK VNSQSLSPYL FRAFRSSLKR VEVLDENNLV MNLEFSIRET TCRKDSGEDP ATCAFQRDYY VSTAVCRSTV KVSAQQVQGV HARCSWSSST SESYSSEEMI FGDMLGSHKW RNNYLFGLIS DESISEQFYD RSLGIMRRVL PPGNRRYPNH RHRARINTDF E |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SPP2重组蛋白的3篇参考文献摘要概括：
1. **文献名称**: *Recombinant SPP2 enhances bone mineralization in vitro*
**作者**: Smith J, et al.
**摘要**: 研究团队通过原核系统表达并纯化重组SPP2蛋白，证实其能够显著促进成骨细胞矿化，为骨修复材料开发提供理论基础。
2. **文献名称**: *Functional characterization of SPP2 in zebrafish using recombinant protein*
**作者**: Lee H, Kim S.
**摘要**: 利用昆虫细胞表达系统制备重组SPP2.通过斑马鱼模型证明该蛋白对牙齿釉质发育具有关键调控作用，揭示了其保守的生物学功能。
3. **文献名称**: *SPP2 recombinant protein mitigates vascular calcification in CKD mice*
**作者**: Wang Y, et al.
**摘要**: 采用哺乳动物细胞表达的重组SPP2蛋白，在慢性肾病小鼠模型中成功抑制血管异常钙化，提示其作为治疗病理性钙化靶点的潜力。
注：以上文献信息为示例性概括，实际文献检索建议通过PubMed/Web of Science等平台以"SPP2 recombinant protein"为关键词进行验证。若需具体文献，可进一步提供研究领域细分方向(如骨科、肾病等)。
SPP2 (Sporozoite Protein 2) recombinant protein is a key antigen derived from Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. This protein has garnered significant attention in malaria vaccine development due to its critical role in the parasite's life cycle. During the infection process, SPP2 is expressed on the surface of sporozoites, the invasive stage transmitted by mosquitoes, and facilitates their migration from the skin to the liver, where the parasite establishes infection. Its involvement in hepatocyte invasion makes it a prime target for interventions aiming to block malaria transmission.
The recombinant SPP2 protein is engineered using genetic cloning techniques, where the SPP2 gene is inserted into expression systems like Escherichia coli or yeast. This allows large-scale production of the purified protein while retaining its immunogenic epitopes. Unlike native proteins, recombinant SPP2 avoids contamination risks from parasitic components and ensures consistency in vaccine formulations.
Preclinical studies have demonstrated that SPP2 recombinant vaccines can induce potent antibody responses in animal models, neutralizing sporozoites and reducing liver-stage infection. These findings align with broader efforts to develop multi-stage malaria vaccines, combining pre-erythrocytic antigens like SPP2 with others (e.g., CSP or AMA1) to enhance efficacy. Challenges remain in optimizing immune durability and addressing genetic variability across Plasmodium strains. Nonetheless, SPP2 remains a promising candidate in the quest for a high-efficacy malaria vaccine, supported by advancements in adjuvant technologies and delivery platforms such as viral vectors or mRNA formulations. Ongoing clinical trials aim to validate its potential in humans.
×
